News
- Homepage
- >
- News
Latest news
-
20 March 2024SERB Pharmaceuticals grants exclusive license to M8 Pharmaceuticals, an Acino company, to bring Voraxaze® (Glucarpidase) to cancer patients in Latin AmericaSERB Pharmaceuticals, a global specialty pharmaceutical company, and M8 Pharmaceuticals, an Acino company are collaborating to bring an important drug for cancer patients to Latin America. Under the agreement, M8 Pharmaceuticals is licensed to register, market and commercialize SERB’s supportive oncology product Voraxaze® (glucarpidase) in Latin America.
-
11 December 2023Largest study to date of high-dose methotrexate associated acute kidney injury supports the use of Voraxaze® (glucarpidase)Patients receiving glucarpidase had higher adjusted odds of kidney recovery, shorter time to kidney recovery, and a lower mortality rate. West Conshohocken, PA, 11 December 2023: BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX) associated Acute Kidney Injury (AKI) treated with and without […]
-
21 September 2023BTG Pharmaceuticals, a SERB company, to present data on ricin antidote development programme at the North American Congress of Clinical ToxicologyWest Conshohocken, PA, 21 September 2023: BTG Pharmaceuticals, a SERB company, announced today that SERB will present in vivo data for PR022, a polyclonal antibody in development as an antidote for ricin poisoning, on the first day of the upcoming North American Congress of Clinical Toxicology (NACCT) in Montreal. The presentation, titled “In vivo viability of […]
News archive
Date
Title